鲁索利替尼
医学
贾纳斯激酶
JAK-STAT信号通路
斯达
化疗
临床试验
卵巢癌
肿瘤科
药理学
癌症研究
内科学
癌症
车站3
信号转导
细胞因子
骨髓纤维化
受体
骨髓
酪氨酸激酶
生物化学
化学
作者
Irfan Yunianto,Margaret J. Currie,Kenny Chitcholtan,Peter Sykes
摘要
Abstract Aim This review aimed to describe the potential for therapeutic targeting of the JAK/STAT signaling pathway by repurposing the clinically‐approved JAK inhibitor ruxolitinib in the patients with epithelial ovarian cancer (OC) setting. Methods We reviewed publications that focus on the inhibition of the JAK/STAT pathway in hematological and solid malignancies including OC. Results Preclinical studies showed that ruxolitinib effectively reduces OC cell viability and metastasis and enhances the anti‐tumor activity of chemotherapy drugs. There are a number of recent clinical trials exploring the role of JAK/STAT inhibition in solid cancers including OC. Early results have not adequately supported efficacy in solid tumors. However, there are preclinical data and clinical studies supporting the use of ruxolitinib in combination with both chemotherapy and other targeted drugs in OC setting. Conclusion Inflammatory conditions and persistent activation of the JAK/STAT pathway are associated with tumourigenesis and chemoresistance, and therapeutic blockade of this pathway shows promising results. For women with OC, clinical investigation exploring the role of ruxolitinib in combination with chemotherapy agents or other targeted therapeutics is warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI